WorldCat Identities

Neuvonen, Pertti J.

Overview
Works: 9 works in 15 publications in 2 languages and 23 library holdings
Roles: Author
Publication Timeline
.
Most widely held works by Pertti J Neuvonen
Studies on the cardiovascular effects of some diuretics by Pertti J Neuvonen( Book )

5 editions published in 1971 in English and held by 11 WorldCat member libraries worldwide

Kliininen farmakologia ja lääkehoito( Book )

2 editions published in 2002 in Finnish and held by 3 WorldCat member libraries worldwide

Kliininen farmakologia( Book )

2 editions published in 1994 in Finnish and held by 3 WorldCat member libraries worldwide

Glucuronidation of clopidogrel by human UGT enzymes: Major contributions by UGT2B7 and UGT2B17( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans by Matti K Itkonen( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

The oxidation of montelukast is mainly mediated by cytochrome P450 (CYP) 2C8, but other mechanisms may contribute to its disposition. In healthy volunteers, we investigated the effects of two widely used P2Y(12) inhibitors on montelukast pharmacokinetics. Clopidogrel (300mg on day 1 and 75mg on day 2) increased the area under the plasma concentration-time curve (AUC) of montelukast 2.0-fold (90% confidence interval (CI) 1.72-2.28, P < 0.001) and decreased the M6:montelukast AUC(0-7h) ratio to 45% of control (90% CI 40-50%, P < 0.001). Prasugrel (60mg on day 1 and 10mg on day 2) had no clinically meaningful effect on montelukast pharmacokinetics. Our results imply that clopidogrel is at least a moderate inhibitor of CYP2C8, but prasugrel is not a clinically relevant CYP2C8 inhibitor. The different interaction potentials of clopidogrel and prasugrel are important to consider when antiplatelet therapy is planned for patients at risk for polypharmacy with CYP2C8 substrates
Intraconazole interacts with felodipine by Pertti J Neuvonen( )

in English and held by 1 WorldCat member library worldwide

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : Objective: Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1 gene) is a hepatic uptake transporter, and its genetic variability is associated with pharmacokinetics and muscle toxicity risk of simvastatin. We examined the possible effects of variations in the SLCO1B1 gene on the pharmacokinetics of lovastatin in a prospective genotype panel study. Participants and methods: Seven healthy volunteers with the SLCO1B1 * 1B/ * 1B genotype, five with the SLCO1B1 * 5/ * 15 or * 15/ * 15 genotype, and 15 with the SLCO1B1 * 1A/ * 1A genotype (controls) were recruited. Each study participant ingested a single 40-mg dose of lovastatin. Plasma concentrations of lovastatin (inactive lactone) and its active metabolite lovastatin acid were measured up to 24 h. Results: In the SLCO1B1 * 5/ * 15 or * 15/ * 15 genotype group, the geometric mean C max and AUC0-24 of lovastatin acid were 340 and 286% of the corresponding values in the SLCO1B1 * 1A/ * 1A (reference) genotype group (P <0.005). In contrast, the AUC0-24 of lovastatin acid in the SLCO1B1 * 1B/ * 1B genotype group was only 68% of that in the reference genotype group (P =0.03). No statistically significant association was observed between the SLCO1B1 genotype and the pharmacokinetics of lovastatin lactone. Conclusion: SLCO1B1 * 5/ * 15 and * 15/ * 15 genotypes markedly increase the exposure to active lovastatin acid, but have no significant effect on lovastatin lactone, similar to their effects on simvastatin and simvastatin acid. Accordingly, it is probable that the risk of muscle toxicity during lovastatin treatment is increased in individuals carrying the SLCO1B1 * 5 or * 15 allele. The SLCO1B1 * 1B/ * 1B genotype is associated with reduced lovastatin acid concentrations, consistent with enhanced hepatic uptake
Effects of carboxylesterase 1 single nucleotide variations on the pharmacokinetics and pharmacydynamics of clopidogrel( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer—Which Factors Matter?( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract : We investigated factors affecting analgesic oxycodone concentrations after breast cancer surgery in 1, 000 women. Preoperatively, we studied heat and cold pain sensitivities and anxiety scores. Postoperatively, rest and motion pain intensities were measured and intravenous oxycodone was administered until satisfactory analgesia. At this point, the mean oxycodone concentration (variation coefficient) was 33.3 ng/mL (66%) and it was 21.7 ng/mL (69%) when the patient requested oxycodone again. At both time points, the concentrations varied >100‐fold between individuals. The analgesic oxycodone concentration was increased by 21.3% per motion pain intensity score on a 0–10 scale and by 22.3% if axillary clearance was performed instead of sentinel node biopsy ( P < 0.001). Forty‐seven women who were older and less anxious than others ( P < 0.01) required no oxycodone. Anxiety, age, chronic pain, or preoperative pain sensitivity were not independently associated with the analgesic oxycodone concentration. CYP2D6 and CYP3A genotypes did not affect analgesic concentration or duration of analgesia
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.92 (from 0.67 for Intraconaz ... to 0.97 for Kliininen ...)

Alternative Names
Pertti J. Neuvonen clinical pharmacologist, professor emeritus (Univ. of Helsinki, Finland)

Pertti Neuvonen

Pertti Neuvonen dokter

Languages